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SLE is an autoimmune inﬂammatory disease in which various pro- and anti-inﬂammatory cytokines, including TGF-β, IL-10,
BAFF, IL-6, IFN-α,I F N - γ, IL-17, and IL-23, play crucial pathogenic roles. Virtually, all these cytokines can be generated by both
innate and adaptive immune cells and exert diﬀerent eﬀects depending on speciﬁc local microenvironment. They can also interact
witheachother,formingacomplexnetworktomaintaindelicateimmunehomeostasis.Inthispaper,weelaborateontheabnormal
secretion and functions of these cytokines in SLE, analyze their potential pathogenic roles, and probe into the possibility of them
being utilized as targets for therapy.
1.Introduction
Systemiclupuserythematosus(SLE)isaheterogenicautoim-
mune inﬂammatory disease. Though the pathogenesis of
SLE is still incompletely deciphered, putative causations
are deemed to be environmental factors on a diseaseprone
genetic background, the former including pathogenic micro-
organisms which elicit both innate and adaptive immune
responses. Unrestricted hyperactivation of the immune sys-
tem may lead to the overproduction of autoantibodies, im-
mune complex deposition, inﬂammatory cytokine release,
and eventually disease onset. Currently, the treatment for
SLE has evolved from conventional drugs such as corti-
costeroids and immunosuppressants to biologic-targeting
therapies, among which cytokines are the most important
therapeutic targets.
Cytokines are soluble factors which are mostly generated
by immune cells and in turn play crucial roles in the dif-
ferentiation, maturation, and activation of various immune
cells.Abnormalreleaseorfunctionsofdiversecytokineshave
been identiﬁed in SLE patients and animal models both in
vitro and in vivo. These cytokines may exert either proin-
ﬂammatoryoranti-inﬂammatoryeﬀects,orboth,depending
on speciﬁc local microenvironments. They are also critical
mediators that bridge innate and adaptive immune systems,
constituting a rather complex immune response network.
The abnormalities of various cytokines may reﬂect the
imbalance among diﬀerent immune cell subsets, such as
Th1/Th2 and Th17/Treg, thus contributing greatly to SLE
pathogenesis. To understand these cytokine abnormalities
may be beneﬁcial in ﬁguring out the pathogenesis of SLE and
developing eﬀective targeting therapeutics. In this paper, we
focusonseveralhotspotcytokinesandintroducesomerecent
advances of these cytokines in SLE.
2. Anti-InﬂammatoryCytokines
2.1. TGF-β. Three isoforms of transforming growth factor
β (TGF-β) have been identiﬁed in mammals, namely, TGF-
β1, TGF-β2, and TGF-β3, with TGF-β1 being predomi-
nantly expressed in the immune system [1]. TGF-β can
be produced by both innate and adaptive immune cells,
such as monocytes/macrophages, dendritic cells (DCs),
and T lymphocytes, whereas regulatory T cells (Treg) are
demonstrated to be the major source [2]. TGF-β exerts its2 Journal of Biomedicine and Biotechnology
regulation of target cell function primarily through a Smad-
dependent pathway. By binding to its membrane receptor,
TGF-β triggers the activation of TGF-β receptor complex,
resultinginnucleartranslocationofSmad2/3transcriptional
factors, subsequently causing transcription of target genes
[3].
TGF-β has both immunoregulatory and proinﬂamma-
tory properties dependent on diﬀerent microenvironments
[4]. In an inﬂammatory milieu, TGF-β is produced by
macrophages upon their phagocytosis of apoptotic cells
and exerts an anti-inﬂammatory eﬀect, reﬂecting a negative
regulation of inﬂammation processes [5]. Apart from its
inhibitory eﬀect on macrophage activation, TGF-β can also
suppress other innate immune cells, such as NK cells, mast
cells, and granulocytes, and modulate the maturation of
diﬀerentiated DCs [3, 6, 7].
TGF-β regulates the adaptive immune system mainly
through two mechanisms: one is to directly inhibit T-
cell proliferation by reducing the production of IL-2 and
controlling the expressions of some cell cycle regulators [8].
The other is to regulate the diﬀerentiation of na¨ ıve CD4+ T
cells into various eﬀector cell subsets, that is, blocking Th1
diﬀerentiation by reducing IL-12 receptor β2 (IL-12Rβ2)
and T-bet expression [9], inhibiting Th2 diﬀerentiation by
decreasing GATA-3 expression and IL-4-mediated STAT6
activity [10], promoting Th17 diﬀerentiation by inducing
RORγt expression [11], and stimulating iTreg generation by
eliciting Foxp3 expression [12].
The abnormality of both serum and urinary TGF-β
expression or signaling has been investigated in various
studies. A recent study which enrolled 42 new-onset SLE
patients revealed that the concentration of serum TGF-β1
was markedly decreased in SLE patients in parallel with
reduced peripheral Treg cells, while urinary TGF-β1l e v e l s
were signiﬁcantly higher in LN patients [13]. Lower TGF-
β serum levels were also observed in patients with discoid
lupus erythematosus, implicating the role of downregulated
TGF-β in tissue injury of lupus patients [14]. Another study
on peripheral blood mononuclear cells (PBMCs) from SLE
patients demonstrated that resistance to the eﬀects of TGF-
β might be present in a good part of SLE patients due to
distinct defected TGF-β1 signaling pathways [15]. A cross-
sectional study revealed that patients with SLE had lower
levels of TGF-β1 which were correlated with disease activity
and CD4+ T, CD8+ T, and natural killer cell counts [16],
suggesting that TGF-β may be a therapeutic target of interest
in SLE. One study on 32 children with active lupus showed
that plasma latent and active TGF-β1 levels were signiﬁcantly
lower and correlated negatively with disease activity, whereas
urinary latent and active TGF-β1 levels were signiﬁcantly
higher and correlated positively with anti-ds DNA titre and
negatively with serum C3 levels, indicating a pathogenic role
ofloweredplasmaTGF-β1andincreasedrenalproductionof
active TGF-β1 in lupus nephritis [17].
In MRL/lpr mice, the increased gene expression of TGF-
β1 in lung tissues could be downregulated by mycophenolate
mofetil (MMF) treatment, which was correlated with pro-
longed survival [18], indicating a protective role of TGF-β in
SLE lung involvement and the possibility of targeting TGF-β
for treatment of lupus. Intriguingly, one study on lupus-
prone NZB/W F1 mice revealed a duel eﬀect of TGF-β in
mediating lupus disease. On the one hand, the expression of
TGF-β in lymphoid tissues was reduced, which might lead to
immune dysregulation and autoantibody production; on the
other hand, the expression of TGF-β1p r o t e i na n dm R N Aa s
well as TGF-β signaling proteins such as TGF-β receptor type
II and phosphorylated SMAD3 increased in target organs
such as kidneys, which might exacerbate tissue inﬂammation
and damage [19].
The capacity of TGF-β to induce Treg generation can
be harnessed in the treatment of autoimmune diseases
like SLE. Current data in this respect mainly come from
experiments on animal models. MRL/lpr mice with active
disease treated with rabbit anti-mouse thymocyte globulin
(ATG) and TGF-β1 acquired decreased proteinuria and
improved long-term survival which were correlated with
reduced glomerular pathology and protein cast formation.
The beneﬁcial eﬀect may be due to augmented CD4+ CD25+
FoxP3+ Tregs induced by ATG + TGF-β1 treatment in
vitro [20]. Antagonizing TGF-β in vivo with an anti-TGF-
β antibody could selectively inhibit chronic ﬁbrotic lesions
of the kidneys in lupus-prone NZB/W F1 mice but demon-
strated no signiﬁcant eﬀect on circulating autoantibody
production [19], implying a complex role of TGF-β in lupus
pathogenesis.
2.2. IL-10. Interleukin-10 (IL-10) is a key immunoreg-
ulatory cytokine that can be produced by almost all
leukocytes, including innate immune cells such as mono-
cytes, macrophages, DCs, mast cells, natural killer cells,
eosinophils, and neutrophils, and adaptive immune cells
such as Th1, Th2, Treg, Tr1, Th3, γδT, CD8+ T, and B cells
[21, 22], and the recently discovered Th17 and Th22 cells
[23, 24], with macrophages, DCs, and Th cells are the major
sources. It has now been established that the production of
IL-10canbeinducedbyToll-likereceptor(TLR)ornon-TLR
signaling in macrophages and myeloid DCs [25].
The activity of IL-10 is mediated by its speciﬁc cell
surface receptor complex, which is composed of α and β
chains and expressed on various cells, in particular immune
cells. Engagement of IL-10 with IL-10R activates the tyrosine
kinases Jak1 and Tyk2 followed by STAT3 phosphorylation,
resulting in target gene activation. IL-10 can inhibit I-kappa-
B kinase (IKK) activity and block DNA binding of NF-
κB already present in the nucleus, thereby blocking NF-κB
nuclear translocation. As NF-κB controls the transcription
of various inﬂammatory cytokines and chemokines, IL-10
may exert its anti-inﬂammatory properties by inhibiting this
transcription factor [26].
The main targets of IL-10 on immune cells are antigen-
presenting cells and lymphocytes. On the one hand, IL-10
inhibited the antigen-presenting capacity of monocytes and
macrophages by downregulating cell surface levels of MHC
class II, costimulatory molecules such as CD86 and adhesion
molecules such as CD58 [27]. IL-10 also inhibited the func-
tion of DCs by downregulating the production of IL-12 and
expressions of MHC class II and costimulatory moleculesJournal of Biomedicine and Biotechnology 3
[28].Ontheotherhand,IL-10promotedthedevelopmentof
a type 2 cytokine pattern by inhibiting the IFN-γ production
of T lymphocytes [29], directly inhibited the proliferation of
CD4+ T cells and production of cytokines such as IL-2, IFN-
γ,I L - 4 ,I L - 5 ,a n dT N F - α [30], consequently impairing cellu-
larimmuneresponses,andregulatesTh1/Th2imbalance.IL-
10alsoreducedthesecretionofIL-23bymacrophages,which
is essential for the existence of Th17 cells [31]. Besides, IL-
10 may function as a potent B-cell stimulator that enhances
activation, proliferation, and diﬀerentiation of B cells [32].
IL-10 decreases apoptosis of autoreactive germinal center
B lymphocytes by increasing their bcl-2 expression, thus
promoting autoantibody production [33].
Abundant studies have demonstrated that serum IL-
10 titers are signiﬁcantly elevated and correlate with lupus
disease activity [34]. The in vitro observation that anti-IL-
10 antibodies could dramatically inhibit immunoglobulin
production by SLE PBMCs corroborated the role of IL-10 in
mediating autoantibody production [32]. IL-10-containing
SLE PBMC supernatants inhibited IL-12 p35 and IL-12
p40 gene expression, thus restoring normal cellular immune
responses by correcting the IL-10/IL-12 imbalance [35]. SLE
patientstreatedwithaspeciﬁcanti-IL-10mAbwerereported
to acquire remission in disease activity [36]. That IL-10
neutralization improved cutaneous manifestations of several
patients rapidly, which was associated with decreased expres-
sion of activation markers on endothelial cells, is consistent
withaproinﬂammatoryeﬀectofIL-10onendothelialcellsin
SLE [36]. In vitro cultured SLE PBMCs administered with an
anti-IL-10 antibody could reduce the apoptosis of CD4+ and
CD8+ T cells and the levels of sFas and sFasL in the culture
supernatant as well as Fas and FasL mRNA expressions in
cultured cells, indicating that IL-10 may trigger apoptosis
of CD4+ and CD8+ T cells via the Fas-FasL pathway, which
might partly explain its pathogenic role in SLE [37]. The
abnormally generated IL-10 might be partly due to elevated
TLR-9 expression on B cells, as experiments showed that
TLR-9 level on peripheral blood B lymphocytes from SLE
patients wassigniﬁcantly correlatedwith disease activity, and
could induce the production of anti-dsDNA antibody and
IL-10 by TLR9-CpG ligation [38].
Experimental data from studies with the NZB/W murine
SLE model exhibited beneﬁcial eﬀects of anti-IL-10 antibod-
ies in delaying lupus disease onset, an eﬀect perhaps medi-
ated by upregulation of TNF-α production [39]. However,
IL-10-deﬁcient MRL-Fas/lpr mice developed exacerbated
disease, associated with augmented production of the Th1
cytokine IFN-γ by CD4+ and CD8+ T cells and IgG2a anti-
dsDNA Abs, suggesting a protective role of IL-10 in lupus
pathogenesis. As exacerbated disease was observed partic-
ularly in young IL-10-deﬁcient mice, one may hypothesize
that IL-10 plays a downregulatory role at an early stage of
lupusdevelopment,while,atlaterphasesofdisease,excessive
production of IL-10 may result in enhanced autoanti-
body production and subsequent formation of pathogenic
autoantibody-antigen complexes [40]. Another study on
NZB/W mice also found that IL-10 produced by CD4 T cells
had a suppressive eﬀect on anti-dsDNA autoantibody pro-
duction, thus exhibiting a beneﬁcial eﬀect in murine lupus,
even in full-blown disease [41]. The contradictory results
of IL-10 may reﬂect the opposite eﬀects of this cytokine
on the two major facets of lupus pathogenesis, namely,
B cells and inﬂammation. One study in a novel congenic
model of lupus, B6.Sle1.Sle2.Sle3 (B6.TC), showed that IL-
10 overexpression signiﬁcantly delayed rather than com-
pletely abolished autoantibody production and decreased
clinical nephritis, with B-cell phenotypes largely unaﬀected
while T-cell activation markedly reduced, demonstrating the
immune-regulatory eﬀect of IL-10 on T cells [42].
3. Proinﬂammatory Cytokines
3.1. IL-6. IL-6 is a pleiotropic cytokine mainly produced by
monocytes,ﬁbroblasts,andendothelialcells,butitssecretion
may also be found in keratinocytes, mesangial cells, and
Ta n dBl y m p h o c y t e s[ 43]. IL-6 receptor consists of two
subunits, IL-6R and gp130. Binding of IL-6 to IL-6R leads
to dimerization of gp130, subsequent activation of gp130-
associated kinase JAK1, and then tyrosine phosphorylation
of gp130, thereof accomplishing the transmission of intra-
cellular signals [44]. The predominant function of IL-6 is to
stimulate the ﬁnal stages of B-cell maturation, causing B cells
to diﬀerentiate into mature immunoglobulin- (Ig-) secreting
plasma cells [44]. It has also been shown recently that IL-
6 can induce antibody production indirectly by promoting
the B-cell helper properties of CD4+ T cells through IL-
21 production [45]. IL-6 can also induce T-cell growth and
cytotoxic T-cell diﬀerentiation through the increase of IL-
2r e c e p t o re x p r e s s i o na n dI L - 2p r o d u c t i o n[ 44]. Besides, in
the presence of TGF-β, IL-6 induces na¨ ıve CD4+ Tc e l l st o
develop into Th17 cells through activation of STAT3 and
induction of the transcription factor RORγt[ 46].
TheabnormalityofIL-6hasbeenfoundinvariouslupus-
prone mouse models. In MRL/lpr mice, serum IL-6 and
soluble IL-6R levels were elevated with age [47]. In IL-
6-deﬁcient MRL/lpr mice, the inﬁltration of macrophages
and deposition of IgG and C3 in kidney were reduced
signiﬁcantly, indicating the stimulating role of IL-6 in lupus
nephritis [48]. In NZB/W mice, while IL-6 promoted lupus
manifestations [49], blockade of IL-6R could modulate the
age-relatedincreaseofanti-dsDNA,reducedproteinuria,and
signiﬁcantly improved mortality [50]. Exogenous adminis-
tration of recombinant IL-6 to female NZB/W mice resulted
in accelerated proteinuria and dose-dependent increases in
mortality [51].
Abnormal IL-6 levels were observed in patients with
SLE in serum and local tissues. Serum levels of IL-6 were
signiﬁcantly elevated and correlated with disease activity
and anti-dsDNA titres [52]. In patients with active lupus
nephritis, the urinary level of IL-6 was higher than that of
normal controls and patients with quiescent renal disease
[53]. The in situ expression of IL-6 gene was also enhanced
along the glomeruli and tubules in lupus nephritis kidneys
[54]. In patients with neuropsychiatric involvement, the
levels of IL-6 in the cerebrospinal ﬂuid were elevated [55].
The raised serum IL-6 presented an inverse correlation
with hemoglobin level, indicating that IL-6 may involve4 Journal of Biomedicine and Biotechnology
in the development of anemia in lupus patients [56].
Moreover, Lupus patients with pulmonary involvement had
higher serum IL-6 levels compared with those without
pulmonaryinvolvement[57].Alateststudyalsorevealedthat
SLE patients with ongoing synovitis and joint deformities
had increased IL-6 which correlated with ESR and anti-
d s D N Al e v e l s[ 58]. Altogether, IL-6 may play most impor-
tant pathogenic role in SLE and mediate multiple organ
damages.
The dominant role of IL-6 in SLE pathogenesis is
to accelerate autoantibody production by promoting the
proliferation of autoreactive B cells. It has been established
by ex vivo experiments that B cells from lupus patients
could secrete heightened quantity of immunoglobulin and
IL-6 blockade signiﬁcantly abolished this spontaneous
immunoglobulin synthesis which was restored with exoge-
nous IL-6 administration [59], indicating the pivotal role of
IL-6inautoantibodyproduction.Amongvarioussubtypesof
B lymphocytes, low density B cells are primarily responsible
for the production of the majority of autoantibodies, and IL-
6 can facilitate these low density B cells from active lupus
patients to diﬀerentiate directly into Ig-secreting cells [60].
At gene level, the aberrant production of IL-6 by SLE B
cells upregulated the positive regulator of recombination-
activating genes (RAG2), namely, p27(Kip1), causing SLE B
cells to become prone to secondary immunoglobulin gene
rearrangements and autoantibody production [61].
The sources and mechanisms of IL-6 overproduction are
multiple. Heightened IL-6 production by SLE B lymphocytes
was observed in various in vitro experiments [52, 59, 61].
Autoreactive T cells in lupus may also produce high levels of
IL-6 [62]. Excessively produced anti-dsDNA autoantibodies
could upregulate the expression of IL-6 in endothelia cells
and stimulate the release of IL-6 from resting mononuclear
cells in a paracrine way [63]. In lupus nephritis, the main
source of IL-6 in the kidney is inﬁltrating monocytes and
macrophages [64], while mesangial cells also produce some
[65]. Studies both in mice and human SLE showed that IL-
6 overexpression could be induced by deregulation of JunB
expression in the epidermis and was suﬃcient to induce
autoantibody production and SLE-like disease [66]. Studies
in the B6.TC mice models of lupus revealed that DCs could
overproduce IL-6 which is necessary for the blockade of Treg
activity [67].
Apart from stimulating autoantibody production by SLE
B cells, the abnormally elevated IL-6 could also contribute to
the pathogenesis of SLE through several other mechanisms.
Studies in one mouse model displayed that Iﬁ202 gene is a
major genetic contribution to the development of SLE. IL-
6 may stimulate its transcription and expression through
STAT3 activation and may contribute to increased suscep-
tibility to the development of lupus by retarding cell cycle
progression and inhibiting apoptosis of immune cells [68].
In the B6.TC lupus-prone mice, increased IL-6 production
was associated with an inhibition of Treg functions, and
neutralizing of IL-6 signiﬁcantly increased suppressive eﬀect
of Treg, suggesting that IL-6 may promote autoimmunity
through interfering with the regulatory functions of Treg
cells [67].
Based on the crucial role of IL-6 in SLE pathogenesis,
biological monoclonal antibodies-antagonizing IL-6 or its
receptor has been developed to treat the disease. Tocilizumab
is a humanized monoclonal antibody against the α-chain
of the IL-6 receptor and prevents the binding of IL-6 to
membrane bound and soluble IL-6 receptor. In an open-
label, phase I study of tocilizumab in SLE, 16 patients
with mild to moderate disease activity were treated with
escalating doses of tocilizumab. At the 8th week of followup,
decreases in circulating plasma cells and serum anti-dsDNA
antibody levels were observed, together with disease activity
improvement, suggesting a speciﬁc eﬀect of tocilizumab
on autoantibody producing cells and a promising aspect
of this drug for SLE treatment, though further studies are
still warranted to establish the optimal dosing regimen and
eﬃcacy [69].
3.2. BAFF. BAFF (B-cell-activating factor) and APRIL- (a
proliferation-inducing ligand), which belong to members of
the TNF superfamily, play crucial roles in the survival and
proliferation of peripheral B lymphocytes and plasma cells
[70]. BAFF, also called Blys (B lymphocyte stimulator), is
a type transmembrane glycoprotein which is mainly syn-
thesized by myeloid cells, such as macrophages, monocytes,
DCs, and basophils, and can also be expressed by stromal
cells, activated T cells, activated and malignant B cells, and
epithelial cells [71]. APRIL is closely related with BAFF. They
are ﬁrstly synthesized as transmembrane proteins and then
cleaved into soluble forms by a furin transferase, with BAFF
cleaved on cell surface while APRIL in the Golgi apparatus
[72]. They present as both homo- and heterotrimers in the
serum and signal by binding with speciﬁc receptors.
There are three types of receptors for soluble BAFF
and APRIL, namely, BR3/BAFF receptor (BAFFR), trans-
membrane activator and calcium-modulator and cyclophilin
ligand interactor (TACI), and B-cell maturation antigen
(BCMA), which are expressed on diﬀerent stages of B
cells. BR3/BAFFR is expressed on nearly all stages of B
cells through their development process, from immature B
cells (pro-B, pre-B, transitional B) in the bone marrow to
primary and activated follicular and marginal zone B cells
in peripheral lymphoid organs, as well as GC and memory B
cells [73]. BCMA and TACI expressions can only be detected
on mature B cells, GC B cells, memory B cells, and plasma
cells, but not on immature B cells [74]. While BAFF binds
to and signals through all the three receptors, APRIL only
signals through TACI and BCMA [75]. Therefore, BAFF
neutralization alone does not aﬀect the plasma cell pool as
they may receive overlapping signals through BCMA and
TACI by APRIL. This is conﬁrmed by studies on mice which
indicate that simultaneous blockade of BAFF and APRIL is
necessary for the decrease of plasma cell numbers [76].
By binding to its receptors which interact with TNF
receptor-associated factors (TRAFs) and activate NF-κB
signal pathways, BAFF can upregulate the expression of
antiapoptotic genes including Bcl-2 and Bcl-XL [77, 78],
downregulate the proapoptotic gene Bim [79], and block the
nuclear translocation of PKCδ in c-myb-dependent manner
[80], thereby protecting self-reactive B cells from apoptosis.Journal of Biomedicine and Biotechnology 5
As B-cell abnormality is essential in autoantibody pro-
ductioninSLE,BAFF/APRILandtheirreceptorsarebelieved
to be involved in SLE pathogenesis. In mice, transgenic
overexpression of BAFF is associated with the development
of lupus-like manifestations, including high levels of cir-
culating anti-dsDNA, proteinuria, and Ig deposition in the
kidneys [81]. Treatment of NZB/W F1 mice with BAFFR-Ig
reduced the circulating levels of anti-dsDNA antibody titres
in parallel with clinical improvement [82]. Patients with SLE
have elevated serum levels of BAFF which are correlated
withincreasedlevelsofautoreactiveantibodies[83].Elevated
levels of BAFF and APRIL in the cerebral spinal ﬂuid (CSF)
of SLE patients have also been reported, and, compared with
patients without CNS involvement, the CFS level of APRIL
was markedly augmented in NPSLE patients [81]. BCMA
expression was substantially higher on SLE B cells, especially
on memory cells and plasmablasts, which might contribute
to the production of IgG autoantibodies [84].
The mechanism of the aberrant BAFF production in
SLE is not fully elucidated. In addition to monocytes and
DCs, which are the main sources of BAFF, SLE T cells
can produce elevated BAFF through signal transduction
pathways triggered by antigens compared to normal T cells
[85]. Both CD4+ and CD8+ T cells from patients with
active SLE expressed intracellular BAFF, whereas those from
normal subjects did not, suggesting a pathogenic role of
T-cell-derived BAFF in SLE [86]. BAFF production can be
induced by pathogen-associated molecular pattern (PAMP)
stimulisuchaspeptidoglycan,CpGdsDNA,andlipopolysac-
charide (LPS) [87] and enhanced by IFN-α,I F N - γ,a n dI L -
10 [88]. Furthermore, CpG dsDNA and LPS can induce
the expression of BAFF receptors in B cells by interacting
with Toll-like receptor (TLR) 9 and 4, respectively [89]. In
vitro experiments demonstrated that SLE B cells released
BAFF/APRIL upon activation, thus initiating a vicious cycle
in which enhanced levels of BAFF and APRIL act in an
autocrine manner to reinforce the systemic activation of the
humoral immune system [90].
Compelling evidence has demonstrated that SLE is asso-
ciated with an increased risk of lymphoma, predominantly
diﬀuse large B-cell lymphoma (DLBCL) [91]. Smedby et al.
found consistent expression of APRIL in the DLBCL from
all SLE patients and a strong association between APRIL
expression and presence of EBV in the lymphoma tissue
[87]. EBV upregulates the expression of APRIL and BAFF
on B cells, which in turn contributes to the persistence
of EBV-infected B cells [92]. Though the exact functional
role of APRIL in DLBCL remains unclear, researchers have
found that endogenous BAFF and APRIL on non-Hodgkin’s
lymphoma (NHL) B cells may prompt them to escape
apoptosis and result in overproliferation [93]. There is also
substantial evidence in support of a role for IL-10 in B-cell
lymphomagenesis [94], and IL-10 serum levels have been
shown to be prognostic factors for NHL, particularly the
DLBCL subtype [95].
Currently,threetypesofmonoclonalantibodiestargeting
BAFF or/and APRIL have been developed for clinical trials
of treating SLE, including belimumab, briobacept, and
atacicept. Belimumab is a recombinant fully humanized
monoclonal IgG1 antibody that binds to soluble BAFF and
inhibits binding of BAFF to its receptors. The Phase I clinical
trial which enrolled 70 patients suﬀering from mild-to-
moderate SLE corroborated belimumab’s biologic activity of
reducing peripheral B-cell numbers and serum anti-dsDNA
antibody level with adequate tolerability and safety [96].
Though the subsequent Phase II randomized, double-blind,
placebo-controlled study of 449 SLE patients did not meet
its primary clinical endpoints of an improvement in Safety of
Estrogen in Lupus: National Assessment and Systemic Lupus
Erythematosus Disease Activity Index (SELENA-SLEDAI)
and“timetoﬂare”endpointsat24weeks,therewasamarked
reduction in circulating naive, activated, and plasmacytoid
B cells [97]. Long-term observation of this trial showed
signiﬁcant decrease in IgG anti-dsDNA titers and increases
in C4 and C3 by week 52 [98]. In two Phase III trials,
namely, BLISS-52 and BLISS-76, which treated 865 and 819
SLE patients, respectively, signiﬁcantly reduced SLE disease
activity (measured using SLE Responder Index, SRI), SLE
ﬂare rates, and the need for prednisone therapy have been
reported at 52 weeks [99, 100].
Briobacept (BR3-Fc) is a recombinant glycoprotein with
two BAFF receptors linked to Fc domain of human IgG1. As
BR3-FcspeciﬁcallybindstoBAFFbutnotAPRIL,ituniquely
targets BAFF. Studies on cynomolgus monkeys revealed that
BR3-Fc decreased B-cell numbers in the periphery and
lymphoid organ [101], but data on clinical trials are still
lacking.
Atacicept is a fully human chimeric molecule composed
of the extracellular domain of TACI integrated with a human
IgG1 Fc domain. Mimicking a soluble receptor, atacicept
binds to both APRIL and BAFF and inhibits signaling
throughBAFFR(BR3),BCMA,andTACI,consequentlyhav-
ing eﬀect on a broader spectrum of B-cell lineages, including
circulating mature B cells, follicular B cells, marginal zone B
cells, as well as bone marrow plasma cells [102, 103]. In a
multicenter, phase Ib clinical trial, SLE patients treated with
atacicept displayed decreased circulating B cells and reduced
serum immunoglobulin levels [103]. A Phase II trial in LN
with atacicept in combination with mycophenolate mofetil
(MMF) was discontinued for the sake of increased risk of
serious infections [104]. A Phase II/III trial in SLE is still
ongoing.
3.3. IFN. The interferon (IFN) cytokine family is composed
of type I IFNs (13 species including IFN-α,I F N - β,I F N - ω,
and IFN-κ), type II IFN (IFN-γ), and the recently described
typeIIIIFNs(IFN-λ)[105].Extensivedatahavesuggestedan
important pathogenic role for IFN-α and IFN-γ in SLE.
3.3.1. IFN-α. The main producers of IFN-α in peripheral
blood are plasmacytoid dendritic cells (pDCs). Viral DNA
or RNA, which are the classical activators of type I IFN pro-
duction, can trigger type I IFN gene transcription via either
Toll-like receptors (TLRs) or the retinoic acid-inducible gene
I(RIG-I)-like receptors [106]. By binding to its receptor, a
heterodimer of IFNAR1 and IFNAR2, IFN-α activates STATs
transcription and promotes increased expression of MHC6 Journal of Biomedicine and Biotechnology
I, DC maturation, T-cell survival, and antibody production
[107].
Extensive studies have revealed a crucial role for IFN-
α in the etiopathogenesis of SLE [108]. An SLE syndrome
can develop during long-term IFN-α treatment of patients
with chronic infections and malignant disease [109] and dis-
continuation results in remission of symptoms, supporting
a causal relationship between IFN-α and SLE. It has been
established that elevated serum levels of IFN-α positively
correlate with SLE disease activity and the generation
of autoantibodies [110]. Plasmatoid DCs (pDCs) are the
primary sources of IFN-α in lupus patients, which are
abundantinskinandlymphnodesbutsometimesreducedin
number in the peripheral blood [111]. On one hand, pDCs
can be triggered to produce IFN-α by immune complexes;
on the other hand, IFN-α can promote activation of DCs
andantibody-secretingcells,augmentproductionofautoan-
tibodies, whereas suppressing regulatory T-cell development
[112]. In the progress of the above-mentioned vicious cycle,
CD4+ T cells are necessary for IFN-α-driven induction of
anti-dsDNA antibodies and clinical manifestations of SLE
[113].
CSF from neuropsychiatric SLE can induce signiﬁcantly
higher production of IFN-α in a culture system containing
pDC and a source of Ag, compared with CSF from patients
with other autoimmune diseases, indicating an important
pathogenic role of IFN-α in NPSLE [114]. Vasculitis is
believed to be a fundamental pathological change in SLE.
IFN-α may interfere with vascular repair in SLE through
repression of IL-1-dependent pathways and promote loss
of renal function [115]. Activation of the IFN-α signaling
pathway may also be linked to the risk of atherosclerosis by
aﬀecting plaque formation in patients with SLE [116].
T h er o l eo fI F N - α has now been conﬁrmed in lupus-
prone mouse strains. Lupus-prone NZB mice lacking type-
I IFN receptor display signiﬁcantly reduced autoimmunity,
kidney disease, and mortality [117]. However, MRL/lpr
mice that lack the same receptor have accelerated lym-
phoproliferation, autoantibody production, and end organ
disease, suggesting a converse role of IFN-α in the two lupus
models [14]. Exposure to IFN-α in vivo induces lupus in
preautoimmune lupus-prone NZB/NZW F1 (NZB/W) but
not in BALB/c mice [118]. IFN-α m a yp l a yd i ﬀerent roles
in diﬀerent autoimmune background, so data derived from
these strains cannot be readily compared with SLE patients.
Dysregulation of IFN-α in SLE is also evident in gene
expression proﬁles, including genes that regulate type I IFN
pathway and IFN-inducible genes (IFIGs). Genome-wide
association studies (GWASs) have identiﬁed multiple novel
genesthatimpactontypeIIFNpathwayassociatedwithSLE,
including variants of interferon regulatory factor 5 (IRF5),
STAT4, and interferon regulatory factor 7 (IRF7) [119].
Recent studies have demonstrated a close morphological
association between the expression pattern of IFN-inducible
chemokines (MxA,CXCL10) and typical histological features
of cutaneous lupus erythematosus [120].
IFIGs correlating with the production of autoantibodies
and the clinical manifestations of SLE are thought to be
responsible for the immunomodulatory properties of IFN.
The interferon signature is associated with active disease and
the presence of renal and CNS involvement. Global proﬁl-
ing of gene expression in PBMCs has consistently shown
upregulation of IFIGs in SLE patients which are correlated
with disease activity [121]. Data from a recent research
indicates that IFN-induced protein with tetratricopeptide
repeats 4(IFIT4) might contribute to the pathogenesis of
SLE by inducing monocytes to diﬀerentiate into DCs. Data
from murine lupus models have also supported a genetic
contribution of IFN-regulated genes to lupus susceptibility.
Iﬁ202, a chromosome 1q-encoded gene that is induced by
both IFN-α and IFN-γ,i sp o l y m o r p h i ca n dd i ﬀerentially
expressed in lupus and control mice [122].
Current data suggested there exists a reciprocal regu-
lation between TNF-α and IFN-α in human autoimmune
diseases like SLE. RA patients undergoing therapy with TNF-
α antagonists had increased titer of anti-dsDNA antibodies
and developed lupus-like syndrome [123], which indicated
that TNF-α might act as an antagonist of IFN-α.P a l u c k a
et al.’s study showed that TNF-α might regulate IFN-α
production in vitro by inhibiting the generation of plas-
macytoid dendritic cells (pDCs) from CD34+ hematopoi-
etic progenitors and IFN-α release by immature pDCs
[124]. Therefore, TNF-α blockade might result in increased
production and bioavailability of IFN-α in SLE and in
patients receiving anti-TNF-α therapy, leading to elevated
titers of antinuclear antibodies (ANAs) and anti-dsDNA
antibodies, mainly restricted to the nonpathogenic IgM and
IgA isotypes, but no IgG anti-dsDNA antibodies [125].
TNF-α and IFN-α induce diﬀerentiation of distinct types
of dendritic cells, namely, TNF-DCs or IFN-DCs, which
present diﬀerent antigens and produce distinct autoimmune
responses. TNF-α may drive IL-23/IL-17 axis inﬂammation
by promoting monocytes to diﬀerentiate into TNF-DCs
[126] .T N F - D C sh a v eb e e nt e r m e da ss e m i m a t u r ea st h e y
were unable to produce mRNA or proteins of proinﬂam-
matory cytokines such as IL-12. They could protect mice
from EAE via the MHC II/peptide presentation to CD4+ T
cells but induced killing of CD8+ T cells via MHC I/peptide
presentation [127]. In SLE patients, circulating IFN-α may
induce monocytes to diﬀerentiate into IFN-DCs, which then
potently capture apoptotic cells and nucleosomes and then
presenttheseautoantigenstoCD4+ Tcells,thusinitiatingthe
expansion of autoreactive T cells, followed by diﬀerentiation
of autoantibody-producing B cells [128]. IFN-DCs also
proved to be eﬀective in inducing a Th1 type of immune
response and CD8+ T-cell responses against deﬁned antigens
in diﬀerent models [129]. TNF-α, together with IFN-γ,I L - 6 ,
IL-1,andIL-18,arecurrentlyrecognizedasimportantfactors
in the pathogenesis of macrophage activation syndrome
(MAS), which is a life-threatening complication of various
rheumatic diseases including SLE [130, 131], while elevated
levels of TNF-α and IL-6 and a trend to lower IFN-γ were
found in patients with deﬁnite antiphospholipid syndrome
(APS) [132].
In view of the accredited important role of IFN-α in
the pathogenesis of SLE, therapeutic agents targeting this
cytokine are theoretically feasible. From the production
source of IFN-α to its binding receptor complex andJournal of Biomedicine and Biotechnology 7
downstreamsignalingpathway,variouspointscanbeutilized
as therapeutic targets. High-dose steroids are deemed to
be the most eﬀective approach to inhibiting production of
IFN-α by inducing the death of the major producers of
IFN-α,p D C s[ 133]. Currently, at least three monoclonal
antibodies speciﬁc for diﬀerent IFN-α isoforms are in
clinical development. Recent data from MedImmune have
demonstrated inhibition of the IFN signature in PBMC and
in skin biopsies from some lupus patients treated with Medi-
545 [134]. Considering the essential role of type I IFN in
host defense against virus infection, monoclonal anti-IFN-α
antibodies which block the interaction of IFN-α with IFNAR
seem to be safer and more feasible, as antibodies blocking
the IFN receptor might completely inhibit downstream
gene expression and cause more risk of viral infection and
malignancy.
3.3.2.IFN-γ. IFN-γ isgeneratedbybothinnateandacquired
immune cells, particularly T cells and NK cells. IFN-γ recep-
tor (IFN-γR),whichiswidelydistributedonallkaryocytes,is
composed of two subunits, IFN-γR-1 and -2, and transduces
signals through JAK/STAT pathway [135]. It is commonly
accepted that IFN-γ can promote Th1 polarization, facilitate
speciﬁc cytotoxicity by increasing the expression of MHC
class-I and -II molecules, and boost antigen processing and
immunoglobulin switching.
IFN-γ has long been categorized as a typical Th1
cytokine, and its production was demonstrated to be
decreased in SLE patients [136]. However, enhanced level
of IFN-γ has been recently reported in SLE patients, which
mightcontributetoSLEpathogenesisbyinducingBAFFpro-
duction [137]. While the ratio of IFN-γ-producing cells are
found to be higher in SLE patients which are correlated with
elevatedserumlevelofIFN-γ [138],invitroexperimentsalso
indicate that PBMCs from SLE patients may produce larger
amount of IFN-γ in response to anti-CD3 plus costimulating
mAb stimulation [22]. During exacerbation of SLE, IFN-
γ is synthesized in larger amount which may result in the
tissue damage observed [139]. On genetic level, the mRNA
levels of T-bet and IFN-γ as well as the relative expression
levels of T-bet/GATA-3 and IFN-γ/IL-4 are signiﬁcantly
higher in SLE patients than those of normal controls [140].
Lupus nephritis (LN) patients show a predominant Th1
phenotype with a high IFN-γ expression in peripheral blood
and glomerular that parallels the severity of renal damage
[141]. The serum levels of C3, C4, and anti-dsDNA antibody
exhibit a signiﬁcantly positive correlation with glomerular
expression of T-bet and IFN-γ [142].
In murine lupus, the important role of IFN-γ has been
highlighted [143]. Th1 cells help in the production of IgG2a
autibodies, the major subclass of pathogenic anti-DNA
antoantibodies eluted from the murine renal lesions. IFN-
γ upregulates IgG autoantibody production and accelerates
nephritis in vivo, while treatment with anti-IFN-γ antibody
and soluble IFN-γ receptors can delay lupus disease onset
[144]. Gene deletion of IFN-γ or IFN-γ receptor in both
NZB and MRL/lpr lupus-prone mices result in improvement
of renal disease and survival rate [145]. Administration of
IFN-γR-Ig fusion protein to MRL/lpr mice may signiﬁcantly
decrease plasma concentration of IFN-γ and reduce autoan-
tibody production and lymphadenopathy [146]. Diﬀuse
proliferative glomerulonephritis in MRL/lpr mice similar
to that in human LN (WHO class IV) is associated with
autoimmune responses dominated by IFN-γ [147].
Several polymorphisms in the interferon-gamma gene
(IFNG) are associated with susceptibility to SLE, including
single-nucleotidepolymorphismSNP(rs2430561)locatedin
an NF-κB binding site [148]. The expressions of other IFN-γ
inducible genes, such as IP-10 or Mig, are increased in SLE
monocytes [149]. STAT-1 is a critical component in both
IFN-α and IFN-γ signaling pathways. STAT-1 expression
is increased in PBMCs from SLE patients and correlated
signiﬁcantly with disease activity and with the IFN-inducible
expression of CD95 and HLA-DR. A lately described gene
polymorphism in the 3  Repair exonuclease (Trex1) induced
by IFN-γ was reported to be associated with SLE [150].
TargetingtherapyforIFN-γ hasbeensuccessfullyapplied
to lupus mice [138], and treatment with humanized anti-
IFN-γ mAb or recombinant IFN-γ-Ig fusion protein may
provide a novel therapeutic strategy for this intractable
disease in human.
3.4. IL-23/IL-17. IL-23 is a heterodimeric cytokine com-
posed of a unique p19 subunit and a common p40 subunit
shared with IL-12, mainly secreted by antigen presenting
cells, and activates the transcription factor STAT4. The IL-
23 receptor, IL-23R, is present on NK cells, DCs, T cells,
monocytes, and macrophages [151]. IL-23 aﬀects IFN-γ
production, stimulates Th1-cell responses, activates memory
T cells, and enhances inﬂammation by stimulating the
production of proinﬂammatory cytokines. IL-23 is also
essential to promote the expansion and survival of IL-17-
producing cells, including Th17, γδT, and double negative
T( C D 3 + CD4− CD8−, DNT) cells [152].
Though IL-23 is generally regarded as a critical
pathogenic factor in some organ-speciﬁc autoimmune dis-
eases such as experimental autoimmune encephalomyeli-
tis (EAE) and collagen-induced arthritis (CIA) [153], its
abnormality has been recently reported in SLE patients
t o o .m R N Ae x p r e s s i o n so fp 4 0a n dp 1 9s u b u n i t sa r e
increased in PBMCs of untreated SLE patients compared
with immunosuppressor-treated ones and higher in active
SLE patients (SLEDAI >10) than in inactive ones, indicating
that IL-23 is responsive to the therapy and might be a
good marker for SLE remission [154]. IL-23 can stimulate
CD4+ T cell to produce IL-17 and IFN-γ, which is related
to the development and maintenance of the disease process
in SLE [155]. Clinical and pathologic measures of lupus
nephritis were thoroughly abrogated in IL-23R-deﬁcient
MRL/lpr mice, suggesting an indispensable part of IL-23
in kidney involvement. Despite the above ﬁndings, IL-23R
polymorphisms do not appear to play an important role in
the susceptibility or severity of SLE [156].
IL-17,commonlyknownasIL-17A,isaproinﬂammatory
cytokine with multiple functions in the regulation of tissue
inﬂammation. So far, six diﬀerent IL-17, namely, IL-17A8 Journal of Biomedicine and Biotechnology
Table 1: Cytokine functions in diﬀerent development phases of SLE.
Phases of SLE development Involved cytokines Main functions
Susceptibility IFN-α Increase MHC-I expression, upregulate Iﬁ202 gene
Initiation IFN-α Promote DC maturation, inhibit Treg
IFN-γ Increase BAFF, MHC-I/II, initiate Th1 cell response
IL-6 Promote Th17 and plasma cells, inhibit Tregs
diﬀerentiation, reduce apoptosis of T, B lymphocytes
Propagation BAFF Stimulate B-cell expansion and antibody production
IL-23, IL-17 Promote T and B cell activation, stimulate Th17
diﬀerentiation
Regulation/resolution IL-10 Downregulate IFN-γ and IL-23, reduce apoptosis of T,
Bl y m p h o c y t e s
TGF-β Inhibit Th1 and Th2 response, induce Treg and Th17
diﬀerentiation
Th2
Th1
Th17
IL-10
IL-10
IL-6
IL-6
IL-17
IL-17
IL-23
IL-23
IL-23R
IL-4R
IL-4
IL-12
GATA3
STAT6
BAFF
Treg Jak/STAT↑
TGF-β
TGF-β
TGF-β
TGF-β
TGF-β↓
IL-6↑
BAFF↑
IL-17↑
IL-23↑
Treg↓
IL-10↑
IFN-α↑
IFN-γ↑
Th1↑
Th2↑ B↑
Th17↑
Serum cytokine changes in SLE Peripheral lymphocyte changes in SLE
B
BAFF-R
APC
Th0
T-bet
STAT4
Foxp3
Antibody
ROR-γt
STAT3
TGF-βR
TGF-βR
IL-6R/gp130
IL-12Rβ2
IFN-γ
IFN-γ
IFN-α
CD28/CTLA-4
TCR
CD40L
ICOS
CD80/CD86
MHC-II
CD40
ICOSL
CD28/CTLA-4
TCR
CD40L
ICOS
CD80/CD86
MHC-II
CD40
ICOSL
−
−
IFN-γ↓
IL-23↓
Treg↓ Th17↑
MHC-I↑
Treg↓
BAFF↑
MHC-I, II↑
Th1↑
Bim↓
Bcl-2↑
Bcl-XL↑
Bcl-2↑− →apoptosis↓
STAT3↑− →Iﬁ202gene↑− →apoptosis↓
Jak1↑− →RAG2 gene↑− →p27↑− →plasma cell↑
NF-κB, Jnk↑− →T cell activation
in synergy with BAFF−→B cell activation
STAT4↑− →Iﬁ202 gene↑
DC maturation−→IFN-α↑
Figure 1: Cytokine network that links innate and adaptive immunity. This ﬁgure illustrates the functions of some key cytokines secreted
by several most important types of immune cells. APC refers primarily to monocytes, macrophages, and dendritic cells. In SLE, TGF-β and
IL-10 mainly exhibit anti-inﬂammatory eﬀects, while IL-6, BAFF, IFN-α,I F N - γ, IL-17, and IL-23 function as proinﬂammatory cytokines.
These cytokines have cross-talks by aﬀecting one another, thereafter constituting a complex network.
to F, have been described and are structurally homologous
to each other. The IL-17 receptor (IL-17R) is distributed
ubiquitously in various tissues, and its engagement activates
both transcription factor NF-κB and kinase Jnk pathways
[157]. IL-17 has a key role in tissue neutrophil recruitment
and helps the clearance of pathogens such as extracellular
bacteria. IL-17 is produced by several cell types including
activated T-cell subsets (CD4+,C D 8 +,C D 4 − CD8−, γδT
cells), natural killer cells, and neutrophils [158].
The pathogenic role of IL-17 has been observed in EAE,
CIA, inﬂammatory bowel disease (IBD), and SLE [159]. IL-
17 facilitates T-cell activation and inﬁltration into tissues
by upregulating the expression of intercellular adhesion
molecule-1 (ICAM-1) [160]. It can also act in synergy with
BAFFtoinﬂuenceB-cellproliferationandantibodysecretion
[161]. IL-17 may promote autoantibody production, and IL-
17-producing cells are found in aﬄi c t e do r g a n si nh u m a n
SLE patients and lupus-prone mice [162]. Th17 and DNT
cells are expanded in the peripheral blood of SLE patients
and account for the increased production of IL-17 [163].
The urinary expressions of Th17-related genes (ROR-γt,
IL-17, and IL-23) are increased in SLE patients and are
inversely correlated with kidney biopsy as well as systemic
and renal lupus activity [164]. Migration of IL-17-producingJournal of Biomedicine and Biotechnology 9
T cells into the kidneys of MRL/lpr mice is driven by locally
produced chemokines such as CXCR3. Genetic silencing
of genes involved in the increased production of IL-17 in
lupus-prone mice and treatment of those mice with biologic
agents that result in decreased IL-17 production leads to
disease mitigation [165]. Th17 cells mediate accelerated
ischemia/reperfusion-induced intestine injury in MRL/lpr
mice, while IL-23-deﬁcient mice display signiﬁcantly less
intestinal damage [166].
IL-23 is essential to promote the expansion and survival
of IL-17-producing cells. Rapid IL-23/IL-17-mediated neu-
trophil responses might be important for initial control of
the infection, but dysregulation of the pathway can break
tolerance and lead to severe autoimmune pathologies such
as multiple sclerosis, rheumatoid arthritis, psoriasis, and
Crohn’s disease [167]. The importance of IL-23/IL-17 axis
in human lupus and lupus model mice has been validated.
Plasma IL-12, IL-17, IL-23, and CXCL10 concentrations and
the number of Th17 cells are signiﬁcantly elevated in SLE
patients than those of control subjects, and proinﬂammatory
cytokineIL-23,canpromotethediseaseseveritybyactivating
pathogenic Th17 cells [168] .T h e r ei sas t r o n gc o r r e l a t i o n
between IL-17, and IL-23 levels in lupus patients [169]. IL-
23/IL-17A pathway is activated in lupus-prone mice and
is associated with increased Ig deposition and complement
activationinthekidney[162].DNTcellsfromMRL/lprmice
express high amounts of IL-17 and, as disease progressively
worsens, the expressions of IL-17, and IL-23 receptor (IL-
23R) in lymphocytes from these mice are increased. IL-
23R-deﬁcient lupus-prone MRL/lpr mice display decreased
numbers of DNT cells and IL-17A-producing cells in the
lymph nodes and produce less anti-DNA Abs. In addition,
clinical and pathologic measures of lupus nephritis are
abrogated when IL-23R is deﬁcient [170].
A number of key points discussed here constitute a
deﬁnitive rationale for the development of novel drugs or
biologicstoblocktheIL-23/IL-17axistolimitautoimmunity
and organ damage of SLE. The presented experiments doc-
ument the importance of IL-23R-mediated signaling in the
developmentoflupusnephritisandurgetheconsiderationof
proper biologics for the treatment of the disease [171]. The
IL-23/IL-17 axis of inﬂammation and related molecules may
rise as therapeutic targets for treating autoimmune diseases
such as SLE [172].
4. Concluding Remarks
Thecytokinesdiscussedabovearemostlygeneratedbyinnate
immune cells upon stimulation by invading pathogens,
which then induce the activation and proliferation of
adaptive immune cells to perform a joint protective immune
function. A local inﬂammatory milieu will elicit the produc-
tion of anti-inﬂammatory cytokines in a negative feedback,
as well as the generation of regulatory T and B cells, to
prevent overactivation of immune response and subsequent
autoimmune disease. However, there exist various abnor-
malities of multiple cytokines in number and function in
SLE patients, which play crucial roles in disease pathogenesis
(Table 1). These cytokines are downstream products of
activated immune cells and can also exert diﬀerent eﬀects
on the proliferation and function of immune cells. They may
act directly or indirectly on each other, thereby constituting
a complex network (Figure 1).
Currently, the treatment for SLE has evolved from
conventional drugs to biologic agents. Various therapeutic
agents targeting diﬀerent cytokines have been developed to
treat SLE, such as belimumab targeting BAFF, tocilizumab
targeting IL-6, and IFN-γ-Ig fusion protein targeting IFN-
γ. All these biologic agents can improve lupus disease to
diﬀerent extent in both animal models and SLE patients,
but they cannot inhibit the disease progression completely.
The eﬃcacy of these agents is believed to depend on speciﬁc
disease condition, diﬀerent organs involved, and timing of
medication, indicating a spatial and temporal variety of
cytokine expression in SLE, which provide challenge for
cytokine-targeted therapy for SLE and necessitate further
investigation.
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